Here, we review current evidence for the implication of the PD-1/PD-L1 axis in DLBCL and propose a progression model, in two phases, where increased PD-1/PD-L1 signaling and dysregulated cytokines promote anti-tumour immune escape (Figure 2). The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.